Norethisterone acetate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Norethisterone acetate
Norethisterone acetate.svg
Acetato de noretisterona3D.png
Clinical data
Trade names Primolut-Nor, Aygestin, Gestakadin, Milligynon, Monogest, Norlutate, Primolut N, SH-420, Sovel, Styptin
AHFS/ International Drug Names
MedlinePlus a604034
Routes of
Legal status
Legal status
  • In general: ℞ (Prescription only)
Synonyms SH-420
CAS Number
PubChem CID
Chemical and physical data
Formula C22H28O3
Molar mass 340.456 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Norethisterone acetate (NETA) (INN, BAN), also known as norethindrone acetate (USAN), sold under brand names including Primolut-Nor (major), Aygestin (US), Gestakadin, Milligynon, Monogest, Norlutate (US, CA), Primolut N, SH-420 (UK), Sovel, Styptin, and others, is a steroidal progestin of the 19-nortestosterone group with additional weak androgenic and estrogenic activity[1][2] that is used orally as a hormonal contraceptive, in the treatment of gynecological disorders such as abnormal uterine bleeding, and as a component of hormone replacement therapy for menopause.[3][4][5] It is the 17β-acetate ester of norethisterone, and acts as a prodrug to norethisterone in the body.[6][7]


Upon oral ingestion, NETA is rapidly converted into norethisterone by esterases during intestinal and first-pass hepatic metabolism.[8] Hence, it is a prodrug of norethisterone in the body.[6] As such, NETA is a potent progestogen with additional weak androgenic and estrogenic activity (the latter via its metabolite ethinylestradiol).[1][2]

In terms of dosage equivalence, norethisterone and NETA are typically used at respective dosages of 0.35 mg/day and 0.6 mg/day as progestogen-only contraceptives, and at respective dosages of 0.5–1 mg/day and 1–1.5 mg/day in combination with ethinylestradiol.[2] This suggests that NETA is around 50 to 66% as potent as norethisterone.[2] Conversely, the two drugs have been used at about the same dosages in hormone replacement therapy for menopausal symptoms.[2]


Schering AG filed for a patent for NETA in June 1957, and the patent was issued in December 1960.[9] The drug was first marketed, by Parke-Davis as Norlestrin in the United States, in March 1964.[9][10] This was a combination formulation of 2.5 mg NETA and 50 μg ethinylestradiol and was indicated as an oral contraceptive.[9][10] Other early brand names of NETA used in oral contraceptives included Minovlar and Anovlar.[9]

Society and culture[edit]

United States[edit]

NETA is marketed in 5 mg oral tablets in the United States under the brand names Aygestin and Norlutate.[11] In addition, it is available under a large number of brand names at much lower dosages (0.1 to 1 mg) in combination with estrogens such as ethinylestradiol and estradiol as a combined oral contraceptive and for use in hormone replacement therapy for menopausal symptoms.[11]

See also[edit]


  1. ^ a b Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 Suppl 1: 3–63. PMID 16112947. doi:10.1080/13697130500148875. 
  2. ^ a b c d e IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 417–. ISBN 978-92-832-1291-1. Norethisterone and its acetate and enanthate esters are progestogens that have weak estrogenic and androgenic properties. 
  3. ^ F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1450. ISBN 978-0-412-46630-4. Retrieved 12 May 2012. 
  4. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 750. ISBN 978-3-88763-075-1. Retrieved 30 May 2012. 
  5. ^
  6. ^ a b Thomas L. Lemke; David A. Williams (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1316–. ISBN 978-0-7817-6879-5. 
  7. ^ Norethisterone Acetate @
  8. ^ Chwalisz K, Surrey E, Stanczyk FZ (2012). "The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis". Reprod Sci. 19 (6): 563–71. PMID 22457429. doi:10.1177/1933719112438061. 
  9. ^ a b c d Lara Marks (2010). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 73–. ISBN 978-0-300-16791-7. 
  10. ^ a b Robert W. Blum (22 October 2013). Adolescent Health Care: Clinical Issues. Elsevier Science. pp. 216–. ISBN 978-1-4832-7738-7. 
  11. ^ a b "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 6 December 2016.